HRTX News and Press, Heron Therapeutics Inc. From 07/20/20

Evercore ISI has added a healthy 19 stocks in a fresh resumption of its best SMID "core" ideas this month - the research team's very best small and mid-cap stocks. More news on: Cheniere Energy, Inc., WPX Energy, Inc., Chart Industries, Inc., Notable Calls, Healthcare stocks news, Energy s...

Heron Therapeutics Advances Phase 2 Study of CINVANTI Heron Therapeutics Inc. ( HRTX ) announced that it has started its Phase 2 clinical study of CINVANTI. The company has started the trial after receiving a go-ahead from the FDA for its Investigational New Drug application for the drug...

SAN DIEGO , July 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the init...

Heron Therapeutics ( HRTX +3.3% ) perks up on average volume in apparent response to the posting in ClinicalTrials.gov of a Phase 2 clinical trial, GUARDS-1 , evaluating aprepitant in early hospitalized adult COVID-19 patients. More news on: Heron Therapeutics, Inc., Healthcare stocks n...

Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-ca p biotechnology stocks. These companies are often selling at attractive prices, and the...

Yesterday, Heron Therapeutics ( HRTX ) unexpectedly got its second Complete Response Letter ((CRL)) from the FDA in response to its marketing application for HTX-011 to treat post-operative pain. This was a most unexpected response given the compound has both Fast Track and Breakthrough...

Kiniksa Reports Positive Phase 3 Data for Heart Inflammation Drug Kiniksa Pharmaceuticals Ltd. ( KNSA ) announced positive data from its pivotal Phase 3 trial of rilonacept. The drug candidate has been given Breakthrough Therapy designation by the FDA for treating recurrent pericarditis ...

Shares of Pacira BioSciences (NASDAQ: PCRX) are soaring on Monday and are up by 17.5% as of 12:10 p.m. EDT, and this despite the company not reporting any news. We can attribute Pacira's good fortune to one of its potential competitors in the market for postoperative pain, Heron Therapeutic...

Gainers: BioHiTech Global (NASDAQ: BHTG )  +62% . More news on: BioHiTech Global, Inc., PDS Biotechnology Corporation, Ideanomics, Inc., Stocks on the move, , Read more ...

Heron Therapeutics (NASDAQ: HRTX) , a commercial-stage biopharma company, is having a tough go of it today. The company's shares were down by 28.6% as of 10:21 a.m. EDT on Monday.  The culprit? Ahead of the opening bell, Heron announced that the Food and Drug Administration rejected its...